Gene therapy trial highlights RPGR-associated X-linked RP
November 25, 2022
The therapy offers improved retinal sensitivity, visual function, as well as improvements in mobility.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Gene Therapy
Combinining gene therapy and medical device makes progress in RP
November 28, 2022
Investigators who are examining end-stage disease see significant visual recovery in 2 patients.
Combining gene therapy and medical device makes progress in RP
November 23, 2022
Investigators who are examining end-stage disease see significant visual recovery in 2 patients.
Proof-of-concept study advances potential new way to deliver gene therapy
November 02, 2022
The novel genetic engineering approach, tested in mice and laboratory-grown nerve and light-receiving cells, will initially have research applications.
NIH researchers zero in on a new cause of Stargardt disease
November 01, 2022
According to National Institutes of Health/National Eye Institute researchers, the study may help lead to gene therapy for rare inherited blinding disease.
Replay launches HSV gene therapy company focused on retinal eye disease
October 31, 2022
Replay is launching Eudora, an HSV gene therapy company that will target genetic retinal diseases.
NIH scientists discover essential step in recharging the retina
October 27, 2022
A previously uncharacterized area of the protein known as RPE65 spontaneously turns spiral-shaped when it encounters intracellular membranes, or thin structures that surround different parts of a cell.
Moving beyond the drop: CEO provides updates on Oyster Point's pipeline
October 18, 2022
Jeff Nau, PhD, MMS, President and CEO of Oyster Point Pharmaceuticals, provides an appraisal of the company's pipeline as well as updates on recent innovations to hit the market.
UCI-led report illustrates potential of precision genome editing in treating inherited retinal diseases
October 13, 2022
According to University of California, Irvine researchers, current preclinical successes and clinical genome editing approaches for treating inherited retinal degenerative disease and stresses there is hope that in vivo gene editing will be the future treatment paradigm for these diseases.
Nanoscope Therapeutics receives fast track designation from FDA for MCO-010 for treatment of retinitis pigmentosa
October 12, 2022
Nanoscope Therapeutics Inc. announced the FDA has granted Fast Track Designation to MCO-010, an ambient-light activatable multi-characteristic opsin optogenetic monotherapy to restore vision in blind patients, for the treatment of retinitis pigmentosa via intravitreal injection.